About the Company
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GBT News
Global Blood Therapeutics
Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral therapy Oxbryta for sickle cell disease for around $5 billion, according to press reports.
Pfizer puts 91,000 square feet on sublease market following job cuts
Pfizer Inc. has put up for sublease 91,431 square feet in the former South San Francisco headquarters of sickle cell disease drug developer Global Blood Therapeutics, which Pfizer bought two years ...
How Dr. Ted Love, a cardiologist turned biotech executive, sold his sickle cell company to Pfizer for $5.4B
He led a team of scientists and researchers at Global Blood Therapeutics, Inc. (GBT) to bring the sickle cell disease drug Oxbryta into the market. According to Forbes, Dr. Love did not plan to ...
The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations
SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), has awarded grants of ...
INESSS Recommendation to Deny Reimbursement for Multiple Myeloma Treatment is a Global Outlier
FORUS Therapeutics Inc. ("FORUS") is deeply disappointed and disagrees with the recent decision by the Honourable Christian ...
Panbela Therapeutics, Inc. (PBLA)
ASPIRE is a global randomized ... issue of the Journal Blood investigated the effect MINNEAPOLIS, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage ...
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in EuropeConditional marketing authorization is based on ...
Global Blood Therapeutics
This page shows the latest Global Blood Therapeutics news and features for those working in and with pharma, biotech and healthcare. Pfizer has announced the completion of its acquisition of Global ...
Loading the latest forecasts...